GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-3650, Second-Generation TriKE for the Treatment of Hematologic Malignancies
MWN-AI** Summary
GT Biopharma, Inc. has announced a significant milestone in its clinical research journey as it successfully dosed the first patient in a Phase 1 trial for GTB-3650, a second-generation TriKE aimed at treating relapsed or refractory CD33 expressing hematologic malignancies, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). The trial, conducted to evaluate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of GTB-3650, will involve up to 14 patients in seven cohorts, with dosing conducted on a two-week schedule followed by a two-week rest.
This initiative reflects GT Biopharma's commitment to developing innovative therapies through its proprietary natural killer (NK) cell engager TriKE platform, designed to enhance the immune system's ability to combat cancer. The use of camelid nanobody technology in GTB-3650 aims to advance the potency and affinity of the therapeutic, potentially yielding better clinical outcomes for patients with challenging hematologic malignancies.
Michael Breen, Executive Chairman and interim CEO of GT Biopharma, expressed the excitement surrounding this pivotal moment, emphasizing the team’s eagerness to share initial data from the trial, expected in 2025. As the company proceeds through clinical development, attention will be focused on the data generated from this critical research initiative.
Investors and stakeholders interested in the ongoing developments of GT Biopharma can access more details about the trial on clinicaltrials.gov, under the identifier NCT06594445. This advancement positions GT Biopharma at the forefront of immuno-oncology research, aiming to provide novel treatment options for patients battling hematologic malignancies.
MWN-AI** Analysis
GT Biopharma, Inc. (NASDAQ: GTBP) recently marked a significant milestone with the first patient dosed in the Phase 1 trial of GTB-3650, its second-generation TriKE focused on hematologic malignancies. While initial data is anticipated in 2025, this development comes at a critical junction for investors looking at biopharmaceuticals.
The company's innovative approach using camelid nanobody technology could potentially enhance the efficacy of natural killer (NK) cells against relapsed or refractory CD33 expressing hematologic malignancies, such as refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Such advancements could be pivotal amidst increasing competition in the immuno-oncology sphere.
From a market perspective, investors should be mindful of the high-risk, high-reward nature of clinical stage enterprises like GT Biopharma. The dosing of the first patient marks a positive momentum, but the Phase 1 trial's primary focus on safety, pharmacokinetics, and clinical activity means that multiple outcomes need careful assessment to gauge future viability. The size of the trial, limited to approximately 14 patients, highlights the challenges ahead in terms of regulatory approval and market adoption.
GT Biopharma's stock may experience volatility as updates from the trial become available, meaning investors should keep close tabs on developments and think long-term rather than short-term gains. Additionally, an exclusive licensing agreement with the University of Minnesota strengthens the company’s research capabilities and offers a safeguard against competitive pressures.
Ultimately, while there are risks, the potential upside of successful trial outcomes, particularly in under-served cancer indications, could provide substantial rewards for risk-tolerant investors. Evaluating both the clinical progress and strategic collaborations will be essential for discerning the stock’s trajectory in the coming years.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
- Initial data from the Phase 1 trial expected in 2025
SAN FRANCISCO, CALIFORNIA, Jan. 27, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager TriKE ® platform, today announced that the first patient was dosed in a Phase 1 trial evaluating GTB-3650, its second-generation TriKE, for the treatment of relapsed or refractory (r/r) CD33 expressing hematologic malignancies.
“We are thrilled to initiate patient dosing with GTB-3650 in the Phase 1 trial to evaluate the potential in patients with hematological malignancies, which represents a significant milestone for the company. As we continue to progress through clinical development, we eagerly anticipate sharing initial data from the study in 2025”, said Michael Breen, Executive Chairman and interim Chief Executive Officer of GT Biopharma.
GTB-3650 is GT Biopharma’s wholly owned second-generation TriKE. It utilizes camelid nanobody technology, with the potential to improve potency and enhance binding affinity. The Phase 1 dose escalation study will evaluate GTB-3650 in up to approximately 14 patients (seven cohorts) with relapsed or refractory (r/r) CD33 expressing hematologic malignancies, including refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). GTB-3650 will be dosed in two-week blocks, two weeks on and two weeks off, for up to four months based on clinical benefit. The trial will assess safety, pharmacokinetics, pharmacodynamics, in vivo expansion of endogenous patient NK cells and clinical activity. More details can be found on clinicaltrials.gov with the identifier: NCT06594445 .
About GT Biopharma, Inc.
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on our proprietary TriKE ® NK cell engager platform. Our TriKE ® platform is designed to harness and enhance the cancer killing abilities of a patient’s immune system’s natural killer cells. GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE ® technology. For more information, please visit gtbiopharma.com .
Forward-Looking Statements
Certain statements in this press release may constitute "forward-looking statements" regarding future events and our future results. All statements other than statements of historical facts are statements that could be deemed to be forward-looking statements. These statements are based on current expectations, estimates, forecasts, and projections about the markets in which we operate and the beliefs and assumptions of our management. Words such as "expects," "anticipates," "targets," "goals," "projects", "intends," "plans," "believes," "seeks," "estimates," "endeavors," "strives," "may," or variations of such words, and similar expressions are intended to identify such forward-looking statements. Readers are cautioned that these forward-looking statements are subject to a number of risks, uncertainties and assumptions that are difficult to predict, estimate or verify. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. Such risks and uncertainties include those factors described in our most recent annual report on Form 10-K, as such may be amended or supplemented by subsequent quarterly reports on Form 10-Q, or other reports filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements are made only as of the date hereof, and we undertake no obligation to publicly release the result of any revisions to these forward-looking statements. For more information, please refer to our filings with the Securities and Exchange Commission.
TriKE ® is a registered trademark owned by GT Biopharma, Inc.
Investor Relations Contact:
LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com
212-915-2577
FAQ**
What specific safety and efficacy endpoints does GT Biopharma Inc. (GTBP) plan to assess in the Phase 1 trial of GTB-3650 for r/r CD33 expressing hematologic malignancies?
How will the results from the Phase 1 trial of GTB-3650 influence the future development strategy of GT Biopharma Inc. (GTBP)?
Can GT Biopharma Inc. (GTBP) provide insights on the anticipated challenges they may face when evaluating the pharmacokinetics and pharmacodynamics of GTB-3650 during the trial?
What role do you expect the camelid nanobody technology to play in the potential success of GTB-3650 as a treatment option in the Phase 1 trial conducted by GT Biopharma Inc. (GTBP)?
**MWN-AI FAQ is based on asking OpenAI questions about GT Biopharma Inc. (NASDAQ: GTBP).
NASDAQ: GTBP
GTBP Trading
-7.18% G/L:
$0.4084 Last:
1,935,580 Volume:
$0.4508 Open:
